Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Esperion Therapeutics

Request full access

Develops and commercialises oral therapies for the treatment of patients with elevated LDL-C

Plymouth, United StatesFounded 2008Biotech & Life Sciences

About Esperion Therapeutics

Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative lipid-lowering therapies to address cardiovascular disease. The company primarily serves healthcare providers and patients who require effective treatments for managing low-density lipoprotein cholesterol (LDL-C). Operating in the pharmaceutical and biotechnology market, Esperion's business model revolves around the research, development, and commercialization of novel therapies, with a particular emphasis on bempedoic acid and its combination with ezetimibe. The company generates revenue through the sale of its FDA-approved products and potential future licensing agreements. Esperion's commitment to clinical trials and compassionate use programs underscores its dedication to advancing cardiovascular health.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2003
Employees
255
Open positions
22
Dealroom signal
28.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Became $1B as Subsidiary, Biotech and Pharma, Became Thoroughbred as Subsidiary, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Mar 2026
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
BUYOUTOther financing May 2026 $1B $1B ArchiMed ↗
POST IPO EQUITYOther financing Oct 2025 $75M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Esperion Therapeutics website traffic

Latest recorded traffic for Esperion Therapeutics is 19K monthly website visits, up 35.7% over the last three months. Esperion Therapeutics's team grew 0% over the past year.

Latest monthly visits19K 3-month web change+35.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Simcere PharmaSimcere Pharma is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market Nanjing City, China Operational 1,132 — $3.2B
Acerta PharmaClinical research on cancer and autoimmune diseases Oss, Netherlands Acquired
BiovitrumInternational pharmaceutical company that markets specialist pharmaceuticals in several regions globally Solna kommun, Sweden Acquired
Adamas PharmaceuticalsCreate and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology Emeryville, United States Acquired
SecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform Minneapolis, United States Operational
FunPepFunPep is an Industry-university collaboration bioventure company Ibaraki, Japan Operational
Arterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors Atlanta, United States Operational
Amygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction Palo Alto, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Esperion Therapeutics in the Plymouth ecosystem

Live from Dealroom

The Esperion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Aisling Capital
  • Alta Partners
  • Domain Associates
  • Arboretum Ventures
  • Longitude Capital
  • Asset Management Ventures

Series B and later3 investors entered at this stage

  • Pfizer
  • Oberland Capital
  • ArchiMed

Other known investors1 additional known investor

  • HealthCap
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.4%
🇬🇧 United Kingdom1.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Esperion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Esperion Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.